A Geistlich technology originally developed for oral applications can now also be used more broadly in the face, head and neck. The Swiss family-owned company has received European approval for the use of Geistlich Mucograft® collagen matrix in extraoral areas. For patients with skin defects in the face, head and neck this provides an advanced and simple alternative to grafting procedures in which the patient's own skin is harvested.
Geistlich has received this approval for the expanded anatomical placement of Geistlich Mucograft® in accordance with the European Medical Device Regulation (MDR). The product for the regeneration of oral mucosa is now also approved for the treatment and reconstruction of skin defects outside the mouth. Diego Gabathuler, CEO of Geistlich, says, "With this new treatment, Geistlich is strengthening our portfolio in the field of regeneration by offering new solutions for healing of dermal wounds."
Geistlich Mucograft® outcomes are equivalent to skin grafting
Many people suffer from skin defects in the head and neck area caused by various types of skin cancer or injuries. Wound treatment in these areas is complex and often takes time, partly due to the importance of aesthetics. Transplantation of autologous tissue and local flap grafting remain the current gold standard treatments following tumor removal. In these procedures tissue is removed from the patient, creating an additional defect that itself requires treatment. In the CE approval study, it was shown that the use of Geistlich Mucograft® after surgical removal of a tumor in the head and face region, leads to results comparable to autologous skin transplantation, with the major advantage of avoiding the need for an additional operation to harvest the patient's own skin.
Expanded treatment options
"Patients and doctors benefit equally. The elimination of tissue removal not only increases patient comfort, but also simplifies surgical procedures and subsequent wound care", explains Jörg Neunzehn, Clinical Science and Education Manager at Geistlich. "In addition to the benefits for patients, the new treatment method also simplifies internal practice/clinical processes, which can lead to more efficient and faster treatment."
Established product
With our collagen expertise, Geistlich has established Geistlich Mucograft® for intraoral applications as an alternative to free mucosal or connective tissue grafts. The two-layer collagen matrix promotes the regeneration of oral soft tissue without triggering local tissue reactions. Mucograft® also supports wound healing and integrates well with the surrounding tissues. Selection for extraoral indications must consider defect - and patient-specific criteria, and application of the product requires expert instruction. Geistlich Mucograft® for extraoral use will be initially marketed actively in Germany, with further distribution channels and geographies planned.
About Geistlich Pharma AG (Geistlich)
Geistlich is a global leader dedicated to advancing regenerative medicine. Geistlich has been the world market leader in the field of regenerative dentistry for many years. In addition, Geistlich is committed to providing comprehensive support to clinicians in the field of regenerative medicine through scientific research, innovative developments as well as educational programs. Geistlich is a Swiss family-owned company with tradition since 1851. With 15 subsidiaries and 60 distributors, the company reaches around 90 markets and employs over 800 people.
